Inborn Errors of Metabolism Clinical Trial
Official title:
Fit for Transfer: Targeted Interventions for Successful Transition and Transfer of Adolescents With Inborn Errors of Metabolism to Adult Metabolic Services
Verified date | December 2023 |
Source | University Children's Hospital, Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Main aims of this project are - To assess the baseline status-quo of transition and "fitness for transfer" in terms of information about the adult centre and team, organisational and practical skills (blood sampling and sending, how to make an appointment etc.), disease- and treatment-related knowledge, health-related quality of life (HrQoL), and self-efficacy in adolescnets with inborn errors of metabolism. Biochemical or physical parameters as appropriate for the respective diseases from 12 months before are documented. - To provide targeted, structured intervention modules (using available and, if necessary, adapted materials). - To measure the effects of these interventions on information about adult services short-term (within a month) and to re-assess all other baseline status-quo parameters long-term (6 and 12 months later). Psychological assessments will be complemented by biochemical or physical parameters as appropriate for the respective diseases and indicative for transition success.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2025 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 25 Years |
Eligibility | Inclusion Criteria:Patients - with an inborn error of metabolism in the care of a specialized metabolic care unit - requiring specialized adult metabolic care - at least 14 years old - with a disease for which at least one biochemical and / or physical parameter disease marker is well established . Exclusion Criteria: Patients - - with insufficient knowledge of the German - with cognitive impairment to a degree that consent, and participation would be impossible - in an end-of-life situation - with a disease for which no biochemical and / or physical parameter disease marker is well established |
Country | Name | City | State |
---|---|---|---|
Austria | University Childrens Hospital Vienna | Vienna | |
Austria | University Hospital Vienna | Vienna | |
Switzerland | University Childrens Hospital Basel | Basel | |
Switzerland | University Hospital Basel | Basel | |
Switzerland | University Childrens Hospital Bern | Bern | |
Switzerland | University Hospial Bern | Bern | |
Switzerland | University Childrens Hospital Zürich | Zürich | |
Switzerland | University Hospital Zurich | Zürich |
Lead Sponsor | Collaborator |
---|---|
University Children's Hospital, Zurich |
Austria, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease knowledge | interview, semistructured | change from baseline to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT01049854 -
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
|
Phase 2 | |
Completed |
NCT00001596 -
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
|
Phase 2 | |
Withdrawn |
NCT01003912 -
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases
|
Phase 1 | |
Completed |
NCT00744692 -
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
|
Phase 1 | |
Completed |
NCT00692926 -
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
|
Phase 1 | |
Recruiting |
NCT05818566 -
Orphan Drugs for Inherited Metabolic Diseases
|
||
Completed |
NCT05330039 -
Characterization of Intestinal Microbiota in Children With Inborn Errors of Metabolism (IEM)
|
||
Withdrawn |
NCT03866954 -
Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy
|
Phase 2 | |
Completed |
NCT03911089 -
A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD
|
N/A | |
Completed |
NCT03058848 -
Evaluation of PKU Start
|
N/A | |
Suspended |
NCT04399694 -
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
|
||
Terminated |
NCT00654433 -
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
|
Phase 3 | |
Completed |
NCT03168399 -
Evaluation of PKU Explore
|
N/A | |
Recruiting |
NCT00078078 -
Clinical and Laboratory Study of Methylmalonic Acidemia
|
||
Completed |
NCT00328159 -
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids
|
N/A | |
Completed |
NCT04309331 -
Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute
|
N/A | |
Completed |
NCT04709965 -
Evaluating Face-Recognition Technology in Syndrome Diagnosis
|
N/A | |
Recruiting |
NCT06360913 -
Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases
|
N/A | |
Completed |
NCT00309400 -
The Early History of Universal Screening for Metabolic Disorders
|
N/A |